On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®) in patients with ...

This fund can be held in an Investment ISA, SIPP and Investment Account The Fund aims to track the performance of the FTSE All-Share Index, gross of the Ongoing Charge Figure (OCF). The return ...

The Fund aims to provide a higher total return (the combination of capital growth and income), net of the Ongoing Charge Figure, than that of the FTSE Actuaries UK Conventional Gilts All Stocks Index ...

In 2022, the FDA placed a partial clinical hold on Sanofi’s phase III studies on tolebrutinib in MS and myasthenia gravis (MG) indications after the regulatory agency identified cases of drug ...